IL17A and myeloid sarcoma: Gene expression and immunohistochemistry studies of progressive MS brains have shown increased expression of pro-inflammatory cytokines, including interferon-gamma (IFNG), interleukin-17 (IL17), IL21, IL23 and tumor necrosis factor-alpha (TNFA) [15]–[19].